Clean ClAImsFirst Pass

Anterior vs Silna Health

Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.

At a glance

Derived from public facts · a rough scale, not a ranking

AnteriorSilna Health
Pricing model

Enterprise contract (custom) · Payer enterprise deals only

Not published · Quote-based

Speed to go live

Embedded team, deep payer integration

Share data files; Silna handles setup

Automation model

AI copilot · Clinician-in-loop utilization review

Autonomous agents · AI runs benefit checks and auths

Built for

Payers

Small practices, Mid-size groups

Security posture

HIPAA

SOC 2 Type II, HIPAA

Company maturity

3 yrs (est. 2023)

3 yrs (est. 2023)

Financial backing

$64M · Series B

$27M · Series A

Named customers

1 named

None public

Published results

Specific numbers public

Specific numbers public

Documented integrations

1 listed

None documented

Third-party validation

KLAS / analyst cited

None found

Bottom line

  • Pick Anterior if you are a health plan that wants clinician-supervised AI to cut prior auth review time while keeping final decisions with your own staff.
  • Pick Silna if you run a therapy or specialty practice (ABA, PT/OT, behavioral) and want benefit checks and prior auths done for you within weeks of signing.

Anterior

Clinician-led AI for health plan clinical reviews

Founded
2023
HQ
New York, NY
Stage
Series B
Raised
$64M

What it does

  • AI clinical reasoning against payer medical policies
  • Prior authorization review with nurse-in-the-loop workflow
  • Auto-approval of clean requests, flagging of edge cases
  • Embedded clinicians who tune accuracy in production
  • Audit trails for every determination
  • Five-day average deployment into plan workflows

Where it's strong

  • Clinical accuracy of 99.24% in live production was independently validated by KLAS Research.
  • Founded and staffed by clinicians, which helps with medical director buy-in inside plans.
  • Deploys into existing UM workflows in days rather than the multi-month integrations typical of payer software.

What buyers should weigh

  • Sells only to payers, so provider organizations looking for a submission-side tool are not the buyer.
  • Young company with a small number of named reference customers, so diligence on scale is warranted.
  • State laws increasingly require licensed clinicians to make denial decisions, so buyers must define where AI output stops and human judgment starts.

Named customers

Geisinger Health Plan

Integrations

HealthEdge GuidingCare
Full Anterior profile →

Silna Health

Prior auth and benefits automation for therapy providers

Founded
2023
HQ
New York, NY
Stage
Series A
Raised
$27M

What it does

  • Automates benefit checks and eligibility verification before visits
  • Prepares, submits, and tracks prior authorization requests
  • Monitors authorizations and flags expirations and renewals
  • Covers 1,000+ payers across all 50 states
  • Sits alongside existing EHR and practice management systems
  • Built for ABA, PT/OT, speech, psychiatry, and other therapy specialties

Where it's strong

  • Purpose-built for therapy and specialty providers like ABA, where prior auth volume is the core operational pain.
  • Fast deployment because it sits alongside your stack rather than requiring deep EHR integration.
  • Strong reported results: insurance verification cut from 30 minutes to 30 seconds and approvals in hours with a claimed 99.8% success rate.

What buyers should weigh

  • Young company (founded 2023) with a short track record and no large publicly named customers.
  • Narrow front-end focus: it handles benefits and auth, not claims, denials, or the rest of the revenue cycle.
  • The no-integration approach means data lives in a separate staff-facing tool rather than flowing into your EHR automatically.
Full Silna Health profile →

Compare against the rest of Prior Authorization

Deciding between these two?

First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.